Gene Therapy for Hemophilia – From Basic Science to First Approvals of “One-and-Done” Therapies
Over a period of nearly 3 decades, gene therapy for the inherited bleeding disorder hemophilia progressed from basic science to approval of 3 gene therapy drugs that deliver coagulation factor genes to hepatocytes using adeno-associated viral vectors. These molecular medicines can provide multi-year therapy after a single drug administration.